125 related articles for article (PubMed ID: 35907513)
1. Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
Usmani N; Ghosh S; Sanghera KP; Ong AD; Koul R; Dubey A; Ahmed S; Quon H; Yee D; Parliament M; Sivananthan G; Hunter W; Danielson B; Rowe L; McDonald M; Kim JO
Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):317-326. PubMed ID: 35907513
[TBL] [Abstract][Full Text] [Related]
2. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
3. Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Mahalingam D; Hanni S; Serritella AV; Fountzilas C; Michalek J; Hernandez B; Sarantopoulos J; Datta P; Romero O; Pillai SMA; Kuhn J; Pollak M; Thompson IM
Oncotarget; 2023 Jun; 14():622-636. PubMed ID: 37335291
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial.
Kim JO; McDonald MO; Ong A; Koul R; Dubey A; Hunter W; Ahmed S; Quon H; Yee D; Parliament M; Sivananthan G; Danielson B; Rowe L; Ghosh S; Usmani N
Radiat Oncol; 2021 Nov; 16(1):212. PubMed ID: 34736499
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
6. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
7. Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.
Lee YHA; Hui JMH; Chan JSK; Liu K; Dee EC; Ng K; Tang P; Tse G; Ng CF
Prostate; 2023 Jan; 83(1):119-127. PubMed ID: 36178848
[TBL] [Abstract][Full Text] [Related]
8. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
10. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
Ito K; Kobayashi M; Komiyama M; Naito S; Nishimura K; Yonese J; Hashine K; Saito S; Arai G; Shinohara M; Masumori N; Shimizu N; Satoh T; Yamauchi A; Tochigi T; Takezawa Y; Fujimoto H; Yokomizo A; Kakimoto KI; Fukui I; Karasawa K; Tsukamoto T; Nozaki M; Hasumi M; Ishiyama H; Ohtani M; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Yamanaka H;
Cancer; 2020 Sep; 126(17):3961-3971. PubMed ID: 32573779
[TBL] [Abstract][Full Text] [Related]
11. Metformin addition to androgen deprivation therapy effect on cancer prostate patients with type 2 diabetes.
Aboelnaga EM; Aboelnaga MM; Elkalla HM
Diabetes Metab Syndr; 2021; 15(5):102251. PubMed ID: 34428740
[TBL] [Abstract][Full Text] [Related]
12. Metformin use and hospital attendance-related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population-based cohort study.
Lee YHA; Hui JMH; Chung CT; Liu K; Dee EC; Ng K; Tse G; Chan JSK; Ng CF
Cancer Med; 2023 Apr; 12(8):9128-9132. PubMed ID: 36734312
[TBL] [Abstract][Full Text] [Related]
13. An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.
Zhu W; Xu H; Ma J; Guo J; Xue W; Gu B; Sheng L; Yao X; Sun F; Gong J; Qiu W; Ding Q; Jiang H
Urol Int; 2017; 98(1):79-84. PubMed ID: 27684440
[TBL] [Abstract][Full Text] [Related]
14. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.
Smith MR; Malkowicz SB; Chu F; Forrest J; Sieber P; Barnette KG; Rodriquez D; Steiner MS
J Clin Oncol; 2008 Apr; 26(11):1824-9. PubMed ID: 18398147
[TBL] [Abstract][Full Text] [Related]
15. A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.
Freedland SJ; Howard L; Allen J; Smith J; Stout J; Aronson W; Inman BA; Armstrong AJ; George D; Westman E; Lin PH
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):428-437. PubMed ID: 30664736
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.
Bekelman JE; Mitra N; Handorf EA; Uzzo RG; Hahn SA; Polsky D; Armstrong K
J Clin Oncol; 2015 Mar; 33(7):716-22. PubMed ID: 25559808
[TBL] [Abstract][Full Text] [Related]
17. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
[TBL] [Abstract][Full Text] [Related]
18. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up.
Oka R; Utsumi T; Endo T; Yano M; Kamijima S; Kamiya N; Shirai K; Suzuki H
Int J Clin Oncol; 2016 Apr; 21(2):389-396. PubMed ID: 26296528
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.
Nabid A; Carrier N; Vigneault E; Van Nguyen T; Vavassis P; Brassard MA; Bahoric B; Archambault R; Vincent F; Bettahar R; Wilke D; Souhami L
Eur J Cancer; 2021 Jan; 143():64-74. PubMed ID: 33279855
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
